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Activated mast cells trigger edema in allergic and
inflammatory disease. We report a paracrine mecha-
nism by which mast cell-released heparin increases
vascular permeability in vivo. Heparin activated the
protease factor XII, which initiates bradykinin forma-
tion in plasma. Targeting factor XII or kinin B2 recep-
tors abolished heparin-triggered leukocyte-endothe-
lium adhesion and interfered with a mast cell-driven
drop in blood pressure in rodents. Intravital laser
scanning microscopy and tracer measurements
showed heparin-driven fluid extravasation in mouse
skin microvessels. Ablation of factor XII or kinin B2
receptors abolished heparin-induced skin edema
and protected mice from allergen-activated mast
cell-driven leakage. In contrast, heparin and acti-
vated mast cells induced excessive edema in mice
deficient in the major inhibitor of factor XII, C1
esterase inhibitor. Allergen exposure triggered
edema attacks in hereditary angioedema patients,
lacking C1 esterase inhibitor. The data indicate that
heparin-initiated bradykinin formation plays a funda-
mental role in mast cell-mediated diseases.
INTRODUCTION
Mast cells are multifunctional effector cells of the immune
system. Their role in initiating allergic and anaphylactic reactions258 Immunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc.and their activation during certain types of parasitic infection are
well recognized (Marshall, 2004). However, mast cells appear to
make a much broader contribution to other aspects of immune
regulation and are crucial in host defense responses (Galli
et al., 2008). These cells produce an array of vasoactive media-
tors and proinflammatory substances that are either preformed
granule-associated mediators, newly generated lipid mediators,
or belong to a wide variety of cytokines and chemokines (Kales-
nikoff and Galli, 2008).
A well-established concept is that mast cell (MC) mediators,
particularly the vasoactive amines histamine and serotonin,
increase capillary leakage and may rapidly produce edema.
Histamine receptor antagonists are therapeutically used to treat
edema formation and allergic reactions associated with aberrant
mast cell activity, e.g., in asthmatic disease (Theoharides andKa-
logeromitros, 2006). MC secretory granules also contain highly
sulfated polysaccharides, with heparin as a major constituent.
This glycosaminoglycan, which is synthesized exclusively by
MC, has a crucial role as a depot for various mediators and for
themorphology of the granules (Forsberg et al., 1999; Humphries
et al., 1999). Although heparin is one of the most studied mole-
cules, its physiological function in vivo has yet to be determined.
Formation of the vasoactive and proinflammatory peptide
hormone bradykinin (BK) in vitro can be initiated by a variety of
polyanionic surfaces, such as kaolin, glass, ellagic acid, certain
polymers, nucleotides, sulfatides, polyphosphates, misfolded
proteins, and some types of collagen or glycosaminoglycans
(Cochrane and Griffin, 1982; Maas et al., 2011). Generation of
BK involves the plasma contact system proteins factor XII
(FXII), plasma prekallikrein, high-molecular-weight kininogen
(HK), and C1 esterase inhibitor (C1INH). Binding to negatively
Figure 1. MC-Derived Heparin Initiates
Contact System-Mediated BK Formation
Human plasma was incubated for 30 min at
37C with MC-derived glycosaminoglycans and
analyzed for single-chain HK by immunoblotting
and for BK formation by ELISA (means ± SD, n = 8).
(A) Glycosaminoglycans at R4 mg/ml initiated
plasma HK cleavage and BK formation.
(B) MC-derived glycosaminoglycans were incu-
bated with Hase prior to addition of plasma.
(C) Plasma deficient in FXII, FXI, or PK and normal
plasma (NP) was incubated with 20 mg/ml
MC-heparin for 30 min and analyzed for HK
cleavage and BK liberation.
(D) Buffer-treated and heparin-treated (Heparin)
plasma was probed for FXII, PK, single-chain
HK, LK, and FXI zymogen, respectively.
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Mast Cells Generate Bradykinincharged surfaces induces a conformational change in FXII
zymogen, resulting in a small amount of active FXII (FXIIa). FXIIa
cleaves prekallikrein to generate active plasma kallikrein (PK),
which in turn reciprocally activates additional FXII. This amplifica-
tion loop generates sufficient PK activity to liberate BK from HK
by limited proteolysis (Mu¨ller and Renne´, 2008). BK binding to
its cognate B2 receptor (B2R) activates various intracellular
signaling pathways that dilate vessels, induce chemotaxis of
neutrophils, and increase vascular permeability and fluid efflux
(Leeb-Lundberg et al., 2005). Excessive BK generation resulting
from hereditary deficiency of functional C1INH (themajor plasma
inhibitor of FXIIa, PK, and several complement proteases) causes
a life-threatening swelling disorder, hereditary angioedema
(HAE). HAE patients experience recurrent attacks of swelling,
but the stimuli that trigger these periodic episodes of excessive
vascular leakage are poorly defined (Davis, 2008; Zuraw, 2008).
In allergic disease, BK is generated and contributes to increased
vascular permeability (Kaplan andGhebrehiwet, 2010;Proudand
Kaplan, 1988). In vitro, heparin liberates BK by triggering contact
systemactivation (Hojima et al., 1984; Brunne´e et al., 1997; Noga
et al., 1999). However, it is not known whether heparin functions
in mast cell-triggered vascular effects in vivo.Immunity 34, 258–268,Byusinghumanplasmaandendothelial
cells, pharmacological inhibitors in rats,
genetically altered mice, and patients
with inherited C1INH deficiency, we
show that heparin-triggered BK formation
is a critical component of MC-evoked
edema with implications for HAE. Target-
ing heparin-initiated BK formation may
represent a new strategy to protect
against defective barrier function attrib-
uted to MC activation in allergic, anaphy-
lactic, atopic, and inflammatory disease.
RESULTS
Mast Cell-Heparin Activates
the Contact System in Plasma
We isolated high-molecular heparin (500–
750 kDa) from rat peritoneal mast cellsand analyzed the potency of the glycosaminoglycans for BK
generation. Human plasma was incubated with increasing
amounts of heparin and analyzed for HK processing and BK
formation by immunoblotting and ELISA, respectively. Anti-
bodies against the BK sequence in HK revealed that R4 mg/ml
heparin initiated complete plasma HK cleavage (Figure 1A,
top). Consistently, BK was high (>780 ng/ml) in these samples
but low in those treated with buffer (37 ± 22 ng/ml) or with %
2 mg/ml heparin (<35 ng/ml), which was not sufficient to initiate
HK processing (Figure 1A, bar graph). As a control, we incubated
MC-derived glycosaminoglycans with heparinase (Hase) before
adding them to plasma. The enzyme specifically digests heparin.
Hase treatment largely abolished BK formation, triggered by
activated MC-released material. HK conversion started at
>30-fold higher concentrations of the digested (R128 mg/ml,
Figure 1B) versus nontreated glycosaminoglycans, indicating
that heparin accounts for most of the BK-forming activity in
MC-released material. Heparin induces the reciprocal activation
of FXII and PK in ice-cold plasma (Hojima et al., 1984). Consis-
tent with this observation, heparin failed to initiate HK cleavage
and BK production in FXII- or PK-deficient plasma at physiolog-
ical temperature (Figure 1C). In contrast, deficiency of the FXIIFebruary 25, 2011 ª2011 Elsevier Inc. 259
Figure 2. MC-Heparin-Induced BK Forma-
tion Is Dependent on the Negative Charge
Density of the Polyanion
Human plasma samples were supplemented with
1–1000 mg/ml heparin (A), heparan sulfate (B),
dextran sulfate (C), or heparan sulfate sulfated
for 1 min (D) or 10 min (E) and desulfated heparin
(F), incubated for 30 min at 37C, and analyzed
for HK cleavage and BK formation by immunoblot-
ting and ELISA. Means ± SD, n = 8 are plotted.
Immunity
Mast Cells Generate Bradykininsubstrate in the intrinsic coagulation pathway, factor XI (FXI), did
not interfere with HK processing (Figure 1C, lane 2). Heparin
added to normal plasma induced the contact system cascade
with sequential proteolytic activation of FXII, PK, and HK, but
not of low-molecular-weight kininogen (LK, a kininogen gene
splice variant that does not bind PK) or FXI (Figure 1D; Figure S1A
available online). Efficient contact system activation depends on
negative charge density and the size of the FXII-binding surface
(Mu¨ller and Renne´, 2008). We compared heparin and heparan
sulfate for their ability to release BK from HK. Both polysaccha-
rides have similar backbones consisting of alternating iduronic
acids and glucosamines, but differ in charge (heparin has an
average of 2.7 sulfate groups per typical disaccharide unit,
whereas heparan sulfate has an average of 1.0; Capila and Lin-
hardt, 2002). Human plasma was incubated with increasing260 Immunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc.amounts of heparin, heparan sulfate,
and the synthetic polysaccharide dextran
sulfate (a potent FXII activator; Johne
et al., 2006), respectively (Figures 2A–2C).
Heparin and dextran sulfate atR10 mg/ml
each triggered complete conversion of
plasma HK. In contrast, heparan sulfate
up to 100 mg/ml did not induce HK
cleavage, and high concentrations
(1000 mg/ml) of the glycosaminoglycan
induced only minor HK cleavage (36%
of total plasma HK, corresponding to
260 ng/ml BK). To demonstrate that
negative charge density, rather than
a defined structure of the polysaccharide,
is responsible for the enhanced BK-
generating potency of heparin as com-
pared to heparan sulfate, we sulfated
heparan sulfate with sulfuric acid and car-
bodiimide. This method does not cause
depolymerization of the polysaccharide.
Hypersulfation increased the BK-forming
activity of heparan sulfate (Figure 2D).
After 10 min sulfation, the activity of
treated heparan sulfate was similar to
heparin (compare Figures 2E versus 2A).
In contrast, chemical desulfation of
heparin with N,O-bis(trimethylsilyl)acet-
amide largely abolished its BK-forming
activity (Figure 2F). Together, the datashow that heparin initiates BK formation in plasma via activation
of the contact system.
Mast Cell-Heparin Competes with HK for Binding
to Cells
BK formation is tightly regulated and HK binding to the cell
surface heparan sulfate-type proteoglycans protects the BK-
precursor from proteolysis (Renne´ et al., 2005b). Because both
heparin and heparan sulfate bind to the cell-binding site in HK
(Leeb-Lundberg et al., 2005), we reasoned that heparin might
detach cell-bound HK from heparan sulfates as a prerequisite
for efficient BK formation. To test this hypothesis, we incubated
EA.hy926 endothelial cells with 60 nM radiolabeled, uncleaved
HK, removed unbound HK, and added HK-deficient plasma sup-
plemented with heparin (0.05–200 mg/ml). This experimental
Figure 3. MC-Heparin Detaches HK from Endothelial Cells and
Induces BK Release
Uncleaved radiolabeled HK (60 nM) bound to EA.hy926 cells was incubated
with 0.05–200 mg/ml heparin in HK-deficient plasma. After incubation for
30 min at 37C, the samples were analyzed for HK cell binding, HK cleavage,
and BK formation.
(A) The cellular [125I]-HK binding capacity was monitored by a g-counter and
normalized for HK binding in the absence of heparin (set at 100%).
(B) Cleavage of HK was analyzed by immunoblotting with antibodies against
the BK sequence. The relative amounts of uncleaved HK, determined from
immunoblot signal intensities, are given below (untreated control set at 100%).
(C) BK in cell supernatants, determined by ELISA.
Means ± SD of five independent experiments are shown.
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phase. After incubation, we monitored cell-bound HK, HK
cleavage, and BK formation. Heparin dose dependently reduced
HK-cell binding; at R4 mg/ml polysaccharide, cell-bound HKwas reduced to <20% of the amounts of cell-bound HK
measured in the absence of heparin (set to 100%; Figure 3A).
HK detachment from cells was associated with HK cleavage
(Figure 3B) and BK formation (Figure 3C). AtR4 mg/ml heparin,
HK was almost completely cleaved (<7% single-chain HK;
Figure 3B) and BK was formed concomitantly with HK pro-
cessing. BK generation started at >0.4 mg/ml and reached
maximal concentrations (>700 ng/ml) at R4 mg/ml heparin
(Figure 3C). We conclude that heparin has a dual function in
BK generation: the polysaccharide displaces HK from cells and
it activates FXII.
Mast Cell-Heparin Activates the Contact System
in Rodents
To test heparin for triggering BK generation in rodents, we
infused the polysaccharide into the femoral artery of rats and
analyzed BK formation by ELISA. Heparin injection greatly
increased plasma BK (224 ± 93 ng/ml) over buffer-treated
animals (23 ± 16 ng/ml). BK generation was associated with
leukocyte adhesion to vessel walls, as shown in limb cross-
sections from animals that were sacrificed 30 min after chal-
lenge (Figure 4A). Leukocyte-endothelial cell adhesion was
restricted to femoral artery vessel walls downstream of the injec-
tion site and to the ipsilateral vena femoralis. At some sites,
leukocytes had penetrated the endothelial border and invaded
subendothelial tissues (Figure 4B). To confirm that BK mediates
heparin-triggered leukocyte adhesion, we treated rats with the
B2R antagonist Icatibant (Wirth et al., 1991) prior to heparin
infusion. Icatibant did not alter heparin-induced BK plasma
concentrations (181 ± 72 ng/ml) but almost completely blunted
leukocyte adhesion to vessel walls (Figures 4C and 4D). In addi-
tion to being a chemoattractant for neutrophils, BK is a potent
vasodilator (Leeb-Lundberg et al., 2005). Intra-arterial heparin
infusion induced a rapid (within 45 s), pronounced (160 to
50 mmHg), and reversible drop in blood pressure. Blood pres-
sure recovered close to baseline within 30 min. Heparin-trig-
gered hypotonic reaction was almost completely blocked by
Icatibant (Figure 4E). In contrast to intra-arterial application,
subcutaneous or intravenous injection of heparin up to 25 mg/kg
bodyweight (bw) did not change blood pressure nor trigger
leukocyte adhesion (data not shown). To evaluate the role of
heparin-driven BK formation for allergic reactions, we chal-
lenged wild-type (WT), FXII-deficient (F12/), and B2R-defi-
cient (Bdkrb2/) mice that are defective in BK generation
(Pauer et al., 2004) or BK signaling (Borkowski et al., 1995),
respectively, in a model of passive systemic anaphylaxis. We in-
jected mice intravenously with anti-DNP IgE and challenged
them 24 hr later with an intravenous injection of DNP-human
serum albumin (DNP-HSA). WT mice responded with a rapid
and transient drop in systemic arterial blood pressure of 57 ±
24 mmHg, whereas allergen-induced hypotonic response was
decreased in F12/ (23 ± 10 mmHg) and Bdkrb2/ (27 ±
13 mmHg) mice. WT mice pretreated with either FXII-inhibitor
PCK (Kleinschnitz et al., 2006) or Icatibant were protected
from IgE-allergen (Ag)-mediated drop in blood pressure (25 ±
10 and 29 ± 12 mmHg; Figure 4F). We analyzed for HK cleavage
concomitant with BK release in plasma of IgE-Ag-challenged
mice. 10 min after antigen infusion, circulating HK was pro-
cessed and the BK moiety was released from its precursor inImmunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc. 261
Figure 4. MC-Heparin Induces BK-Driven
Leukocytes Infiltration and Hypotension in
Rodents
(A–D) Heparin was infused into the left femoral
artery of untreated (Buffer) or Icatibant (Icat)-
treated rats and the animals were sacrificed
30 min after challenge. Hematoxylin and eosin-
stained cross-sections of limb vessels dorsal to
the heparin infusion site are shown. Leukocytes
adhere to vessel walls (green arrows) in untreated
animals (A) and transmigrate through the endothe-
lial barrier (asterisk, higher magnification) (B). Cor-
responding sections of Icat-treated animals are
shown in (C) and at higher magnification in (D).
Scale bars represent 250 mm in (A) and (C) and
10 mm in (B) and (D). Representative histology of
n = 7 rats in each group is shown.
(E) Heparin was injected into the aorta of rats and
the mean arterial blood pressure was measured
in the left carotid artery in untreated (red line) or
Icat-pretreated (blue line) rats. The times of Icat
and heparin administration are indicated by white
and black triangles, respectively. Means ± SD,
n = 7 rats.
(F) Arterial blood pressure during IgE/Ag-induced
systemic anaphylaxis in WT (red), F12/ (black),
andBdkrb2/ (green) mice orWTmice pretreated
with PCK (gray) or Icat (blue). Infusion of Icat or
PCK and DNP-HSA is symbolized by white and
black triangles, respectively. Means ± SD of
10 mice per group are displayed.
(G) Immunoblot analyses of plasma with anti-
bodies against HK (nonprocessed single-chain
HK; top), the BK sequence in HK (middle), and
FXI (bottom) in plasma of IgE/Ag-treated (lane 1),
IgE/buffer-challenged (lane 2), and buffer-treated
(lane 3) mice (G).
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Mast Cells Generate Bradykininanaphylactic mice (Figure 4G). The activated partial thrombo-
plastin time (aPTT) is a commonly used diagnostic coagulation
test to measure heparin plasma activity. IgE-Ag challenge
largely prolonged the aPTT (>180 s versus 46 s in buffer-treated
animals, n = 15 mice each), corresponding to a heparin plasma
concentration of 4.7 ± 1.7 mg/ml, exceeding the threshold for
activating FXII and PK, and BK formation (Figure 1A). Both
addition of the heparin-antidote protamine and heparinase
normalized the prolonged aPTT in plasma of anaphylactic
mice, confirming that the aPTT prolongation is due to heparin
activity. Cumulatively, the data show that heparin initiates BK
formation via the FXII-stimulated contact system and that this
pathway contributes to mast cell-driven hypotonic reactions in
systemic anaphylaxis in vivo.262 Immunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc.Mast Cell-Heparin Increases
Microvascular Permeability
in a BK-Dependent Manner in Mice
A hallmark of BK-mediated effects is
increased vascular permeability (Han
et al., 2002). To analyze contact system-
mediated leakage in genetically altered
mice, we established an intravital
confocal scanning microscopy technique
to visualize microvascular fluid efflux.Macromolecular FITC-dextran was intravenously injected as
a tracer for paracellular extravasated plasma proteins. A ventral
skin window was incised, and skin was inverted and analyzed
under the microscope. Fluorescence tracer showed blood flow
in microvessels during the experiment. No basal tracer extrava-
sation was detectable for 5 min prior to stimulation, indicating
intact vascular barriers. Topical application of heparin (time point
0 min) provoked leakage from capillaries in WT mice. The initial
leaky spots appeared within 10 min and leakage was maximal
after 20 min (tracer fluorescence intensity 67.1-fold ± 15.2-fold
of initial t = 0 min signal; Figure 5, column 1). Movie S1 is
a 30 min time-lapse presentation of heparin-triggered FITC-
dextran leakage from dermal vessels. To exclude that the
increase in vascular permeability is mediated by a contaminant
Figure 5. MC-Heparin Increases Permeability of Skin Microvessels
Extravasation of FITC-dextran tracer from murine dorsal skin microvessels was recorded by intravital laser scanning fluorescence microscopy in real time.
Heparin was topically applied to the skin of WT, F12/, Bdkrb2/, KitW-sh/W-sh, and Serping1/ mice (columns 1, 3–6). For control, Hase-treated heparin
was applied to the skin of WT animals (column 2) and histamine to F12/ and Bdkrb2/ mice (column 7). Laser scanning images were taken at 5, 10, 20,
and 30 min after stimulation at time point 0 min and are shown in false colors. White represents the highest and black the lowest tracer intensity, respectively.
The scale bar represents 500 mm. Confocal images were recorded with a 103 objective and processed with software EZ-C1, version 2.10 for Nikon. A typical
experiment of a series of n = 10 mice per genotype is shown. Movies S1–S4 show time-lapse recordings of heparin-triggered leakage in mice.
Immunity
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Hase. Hase treatment abolished the activity of the polysaccha-
ride to increase vascular leakage in WT mice (1.6- ± 0.9-fold
at 20 min; Figure 5, column 2). To exclude a contribution of
released endogenous heparin, we tested mast cell-deficient
mice (KitW-sh/W-sh). Exogenous heparin triggered leakage in
mast cell-deficient mice (64.2- ± 4.2-fold; Figure 5, column 5)
to a similar extent as observed in WT animals. Because FXII-
independent mechanisms for PK activation exist (Schmaier,
2008), we analyzed heparin-triggered leakage in F12/ mice
that are defective in contact system-driven BK formation (Pauer
et al., 2004). Intravital microscopy showed that F12/ animals
were resistant to MC-heparin-stimulated alterations in vascular
permeability (1.6- ± 0.7-fold, 20 min; Figure 5, column 3; Movie
S2). To confirm that heparin induces vascular leakage by
releasing BK, we employed Bdkrb2/ mice that are protected
from BK-driven edema (Han et al., 2002). Bdkrb2/ animals
were mostly resistant to heparin-induced increase in perme-
ability (1.7- ± 1.4-fold, 20 min; Figure 5, column 4, Movie S3).
Histamine triggered leakage in FXII- and B2R-deficient mice
(63.3- ± 8.7-fold and 65.8- ± 11.8-fold; Figure 5, column 7), indi-
cating that these animals are susceptible to plasma contact
system-independent edema formation.
Hereditary angioedema is characterized by recurrent swelling
attacks. The underlying disease mechanism is a deficiency in
functional C1INH (Zuraw, 2008). In patients with inheritedC1INH deficiency, poorly defined stimuli trigger contact
system-driven excessive BK formation that increases vascular
leakage (Davis, 2008). To generate an animal model for HAE,
we inactivated the gene encoding C1INH (Serping1) in mice, as
described in the Supplemental Experimental Procedures.
Because mast cells contribute to allergic angioedema (Green-
hawt and Akin, 2007), we investigated heparin as a potential
trigger for vascular leakage in C1INH-deficient (Serping1/)
mice. Intravital microscopy showed that heparin provoked
excessive vascular leakage in Serping1/ versus WT mice
(compare Figure 5, column 6 versus 1; Movie S4 shows leakage
in Serping1/ mice). Leakage began earlier (first leaky spots at
4.5 min versus 10 min), was longer lasting (>50 min), and was
greatly increased in Serping1/ over WT mice (113- ± 17.2-
fold versus 67.1- ± 15.2-fold, t = 20 min). Cumulatively, the
data show that heparin directly triggers vascular leakage by
FXII-dependent BK formation in vivo.
Mast Cell-Heparin Induces Contact System-Driven
Edema in Mice
Weanalyzed the relative importance of heparin-driven BK forma-
tion for mast cell-mediated leakage in mice via the Miles edema
model (Miles and Miles, 1952). Intradermally injected stimuli trig-
gered leakage in dermal vessels that was visualized by Evans
Blue tracer. Extravasated tracer was extracted from the tissue,
quantified by fluorescence emission, and plotted relative to theImmunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc. 263
Figure 6. MC-Heparin Initiates Edema in a BK-Dependent Manner
Evans blue was infused intravenously as a tracer into WT, F12/, Bdkrb2/, KitW-sh/W-sh, and Serping1/mice. Skin edema was induced by intradermal injec-
tions with BK, C48/80, heparin, or saline. Leakage was analyzed after 30 min. Spots with extravasated tracer were excised entirely and dye was extracted and
quantified. Tracer extravasation is plotted relative to leakage in WT mice stimulated with saline. Columns show means ± SD, n = 10 per group. Representative
mouse hides are shown in Figure S3. Figure S1 shows effects of pharmacological inhibitors on heparin-induced edema formation.
Immunity
Mast Cells Generate Bradykininsaline-induced signal in WTmice (set to 1.0, Figure 6; Figure S3).
Basal vascular permeability, assessed in saline-injected skin,
was low (%1.2) in all mice tested. BK-stimulated leakage was
similar in WT and F12/ mice (4.2- ± 0.9-fold versus 4.1- ±
0.7-fold) whereas Bdkrb2/ animals were resistant to BK chal-
lenge (1.2- ± 0.5-fold). Heparin injection induced edema in WT
animals (3.3- ± 0.8-fold), whereas F12/ and Bdkrb2/ mice
were almost completely resistant to heparin-induced leakage
and edema was not significantly different from saline controls
(1.3- ± 0.4-fold versus 1.1- ± 0.3-fold and 1.1- ± 0.3-fold versus
1.1- ± 0.2-fold, p > 0.05). Because congenital deficiency in FXII
and B2R provides protection from edema, we tested pharmaco-
logical inhibition of BK formation and signaling for interference
with heparin-driven leakage. Infusion of PCK or Icatibant prior
to challenge largely reduced heparin-induced edema in WT
mice as compared to untreated animals (1.7- ± 0.5-fold and
1.5- ± 0.5-fold versus 3.0- ± 0.6-fold; Figures S1B and S1C).
Tracer measurements are consistent with the intravital micros-
copy data (Figure 5). Cumulatively, the data show that heparin
is an activator of the contact system and that the polysaccharide
initiates BK-driven edema in vivo. To determine the importance
of heparin-initiated BK formation for activated MC-driven skin
edema, we challenged animals with compound 48/80 (C48/80),
a degranulator of mast cells and eosinophils (Sher and Wadee,
1981). Mast cell-deficient mice were largely resistant to C48/80
stimulation and leakage was low as in saline controls (1.1- ±
0.4-fold versus 1.2- ± 0.3-fold). In F12/ animals, C48/80-stim-
ulated leakage was reduced to 2.3- ± 0.6-fold, i.e., 52% of WT
mice permeability (4.4- ± 0.6-fold). Bdkrb2/ mice confirmed
that FXII-triggered BK formation, rather than other FXII-initiated
pathways, is important for MC-induced edema. In these animals,
C48/80-provoked leakage was reduced to 55% (2.4- ± 0.5-fold)
compared to WT mice. The data indicate that heparin-induced
BK formation accounts for about half of the edema-forming
capacity of activated mast cells. To test heparin for triggering
edema in HAE, we employed our Serping1/ mice. Saline-
induced leakage was 1.2- ± 0.4-fold of WT mice, indicating
that basal vascular permeability in Serping1/ mice was not264 Immunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc.significantly different from that of WT animals (p > 0.05). In
contrast, application of heparin and C48/80 triggered excessive
edema that exceeded the leakage observed in WT mice by
>45% and >60% (4.8- ± 0.7-fold and 18.1- ± 2.0-fold), respec-
tively. However, BK-driven edema was not significantly different
between Serping1/ mice and WT animals (4.3- ± 0.6-fold;
p > 0.05). Taken together, the data show that both heparin and
activated mast cells trigger edema by generating BK.
Allergen-Stimulated Mast Cells Induce
BK-Mediated Edema
To further evaluate the role of the plasma contact system for
mast cell-mediated skin edema under pathophysiological condi-
tions, we set up a model for passive cutaneous anaphylaxis, an
IgE-dependent hypersensitivity reaction (Siebenhaar et al.,
2008). Histamine was applied as positive control and induced
comparable leakage in the skin of WT, F12/, Bdkrb2/,
KitW-sh/W-sh, and Serping1/ mice (4.4- ± 0.5-fold to 4.8- ±
1.0-fold; Figure 7; Figure S4). In contrast, injected Hase-treated
heparin failed to increase leakage over saline (1.1- ± 0.4-fold to
1.3- ± 0.4-fold). We topically sensitized mice by intradermal
anti-DNP IgE injection, challenged them 20 hr later with intrave-
nous injection of DNP-HAS, and analyzed extravasated tracer
after 30 min (Figure 7; Figure S4). Allergen exposure increased
leakage in WT animals to 26.6- ± 5.0-fold (Figures 7A and 7F),
whereas KitW-sh/W-sh mice were resistant to IgE-Ag-mediated
leakage (1.2- ± 0.4-fold), supporting the specificity of the stim-
ulus for MC-driven edema. Under the same conditions, edema
was reduced to 14.6- ± 5.2-fold and 13.6- ± 6.6-fold in F12/
and Bdkrb2/ mice, respectively. The cutaneous anaphylaxis
model is consistent with data from C48/80-stimulated mast cells
and supports a critical role of BK for sensitized mast cell-driven
leakage.
Allergens Exacerbate Edema in C1INH-Deficient Mice
and in HAE Patients
To analyze allergen-stimulated mast cells for initiating edema in
HAE, we challenged Serping1/ mice in our skin anaphylaxis
Figure 7. BK Contributes to Edema in a
Mouse Model of Passive Cutaneous
Anaphylaxis
Mice were intradermally injected with IgE or saline
and challenged 20 hr later by intravenous injection
of DNP-HSA and Evans blue tracer. Tracer was ex-
tracted after 30min from the entire skin edema site
from WT, F12/, Bdkrb2/, KitW-sh/W-sh, and
Serping1/mice. Tracer fluorescence was quan-
tifiedandsignal is plotted relative to saline-induced
extravasated Evans blue in WT mice (dashed lines
represent tracer intensity in a circle of 1.2 cmdiam-
eter within the edema). Means ± SD, n = 10 per
group are shown. Corresponding representative
mouse hides are shown in Figure S4.
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Mast Cells Generate Bradykininmodel. IgE-Ag-activated mast cells provoked excessive edema
in Serping1/ animals (34.1- ± 6.1-fold; p > 0.05 versus WT;
Figure 7; Figure S4). The mouse HAE model identifies allergen-
sensitizedmast cells as an initiator of pathological edema forma-
tion, so we further tested the importance of this concept for the
human disease state. In a survey, 38 well-characterized HAE
patients from Switzerland were asked to report potential triggers
of edema attacks. In 11 out of 38 HAE patients, the onset of
swelling was associated with allergic reactions to food. In three
individuals, edema formation was triggered by hyperimmune
responses to insect toxins, and in a single patient, swelling
episodes were induced by drug hypersensitivity.
In summary, the data identify MC-heparin as an in vivo initiator
of the proinflammatory contact activation system and demon-
strate that heparin-driven BK formation is an important compo-
nent of MC-evoked vascular leakage. These findings suggest
that heparin releasemay have broad clinical relevance in a variety
of edema diseases associated with abnormal mast cell activa-
tion such as angioedema, urticaria, or allergy.
DISCUSSION
For more than 75 years, heparin has been widely used as an anti-
coagulant drug (Jorpes, 1935). The polysaccharide prevents the
formation and extension of blood clots in the circulatory system.
In rare occasions, heparin infusion leads to potentially life threat-
ening side-effects. Within minutes, adverse reactions including
drop in blood pressure, nausea, tachycardia, and edema in
various tissues including the skin and respiratory tract have
been reported (MacLaughlin et al., 2002). These symptoms are
distinct from those of heparin-induced thrombocytopenia (HIT;
a prothrombotic immune-mediated disorder) and reminiscent
of an acute allergic reaction (Warkentin and Greinacher, 2009).
However, the lack of urticaria and pruritis argue against a contri-
bution of mast cell- or basophil-derived histamine or serotonin in
the pathology of these adverse effects (Schwartz, 2008). Our
studies offer a rationale for immediate adverse heparin effects:Immunity 34, 258–268,we show that heparin initiates BK genera-
tion by activating the FXII-driven contact
system in vivo and that this pathway
contributes to MC-driven inflammation,
hypotension, and edema. Supporting
the importance of BK for adverse heparineffects in patients, affected individuals have a severe cough
(MacLaughlin et al., 2002). Elevated plasma concentrations of
BK directly trigger coughing, and cough is a classical side effect
during therapy with angiotensin converting enzyme (ACE) inhib-
itors. ACE inhibitors block the major BK-degrading enzyme and
increase BK plasma concentrations (Leeb-Lundberg et al.,
2005). Vice versa, risk and severity of MC-triggered edema is
increased in patients with low ACE activity (Summers et al.,
2008), whereas incidence of MC histamine-triggered urticaria
is independent of ACE activity (Akcali et al., 2008).
Since November 2007, lethal acute hypersensitivity reactions
in patients receiving commercial heparin largely increased in
number (http://www.fda.gov/cder/drug/infopage/heparin/adverse_
events.htm). A contaminant was identified in suspect prepara-
tions of heparin that was characterized as a nonnatural occurring
oversulfated chondroitin sulfate (OSCS) (Guerrini et al., 2008).
OSCS-contaminated heparin has a greatly increased potency
for activating FXII and triggering kallikrein-mediated BK forma-
tion in human plasma and in a model of experimental hypotonic
shock in vivo (Kishimoto et al., 2008). Infusion of the contact
system activator dextran sulfate in pigs induced transient
systemic hypotension, and Icatibant blocked the drop in blood
pressure (Siebeck et al., 1994). These data are consistent with
heparin-triggered BK formation and hypotension in rats and
mice and support a role of BK in immediate adverse reactions
triggered by negatively charged polysaccharides. BK-forming
activity seems to be dependent on negative charge density of
the polysaccharide rather than on a defined structure. In a recon-
stituted system, the potency to contact-activate FXII decreased
from dextran sulfate and OSCS (4 sulfate residues per disaccha-
ride in average; Guerrini et al., 2008) to heparin (having 2.7 sulfate
residues per disaccharide), whereas heparan sulfate (1 sulfate
residue; Capila and Linhardt, 2002) failed to function as contact
system activator (Hojima et al., 1984). Besides heparin, mast cell
granules contain other negatively charged polysaccharides, e.g.,
chondroitin sulfate E (Stevens et al., 1988). Chondroitin sulfate E
is a potent activator of FXII in plasma (Hojima et al., 1984), isFebruary 25, 2011 ª2011 Elsevier Inc. 265
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Mast Cells Generate Bradykininresistant to Hase digestion (Linker and Hovingh, 1972), and may
account for the minor FXIIa-generating activity in Hase-treated
MC-released material. The potency to activate the plasma
contact system greatly varies among diverse heparin prepara-
tions (Brunne´e et al., 1997; Noga et al., 1999), reflecting
differences in purification procedures, sources of the polysac-
charides, and experimental settings. Some purification proce-
dures of clinically used heparins fragment the polysaccharide
backbone and modify its structure (Fareed et al., 1989).
Heparin appears to have a dual function in FXII activation. The
polysaccharide provides a negatively charged surface that binds
to and induces FXII autoactivation. Concomitantly, antithrombin
III (ATIII), an irreversible inhibitor of FXIIa, binds to a specific pen-
tasaccharide sequence with a unique 3-O-sulfated glucosamine
unit within the heparin backbone (Capila and Linhardt, 2002).
Theoretical models predict a threshold of complete FXII activa-
tion or inactivation that is determined by the kinetic balance
between the catalytic rate of autoactivation and the rate of FXIIa
inhibition (Beltrami and Jesty, 1995). Indeed, heparin-triggered
FXII activation results in a bell-shaped dose response, which is
also observed in OSCS-triggered contact system activation
(Kishimoto et al., 2008).
Ablation of N-deacetylase N-sulfotransferase-2 (NDST-2) in
mice revealed a crucial function of the enzyme for heparin
biosynthesis. NDST-2-null (Ndst2/) mice are deficient in
sulfated heparin and have fewer mast cells (Forsberg et al.,
1999; Humphries et al., 1999). Ndst2/ mast cells have an
altered morphology and less secretory granules that do not con-
tain heparin and show a general deficiency in releasable media-
tors including various mast cell proteases. IgE-mediated
secretion of histamine is defective in NDST-2-null mice, suggest-
ing that heparin regulates MC granule content and function
(Humphries et al., 1999). Because of combined deficiency of
MC-heparin with other mediators such as histamine in Ndst2/
mast cells, these animals do not allow researchers to specifically
address the relative importance ofMC-heparin-driven BK forma-
tion for vascular permeability. IgE-Ag-stimulated leakage in
MC-deficient KitW-sh/W-sh mice reconstituted with Ndst2/
mast cells had high intra-animal variability. Therefore, we
compared IgE-Ag-stimulated edema in KitW-sh/W-sh mice versus
animals with normal MC function versus mice with selective
defects in BK formation or signaling.
During anaphylactic shocks, the aPTT is markedly prolonged
in patients (Lombardini et al., 2009; Mazzi et al., 1994). Consis-
tently, plasma of IgE-Ag-challengedmice is unclottable because
of a systemic heparin concentration of >4 mg/ml, which is suffi-
cient to initiate BK formation. Initially, small amounts of locally
secreted heparin may generate BK activity on the MC surface.
Mast cells express B2R (Dlamini and Bhoola, 2005) and BK stim-
ulation induces MC degranulation (Ishizaka et al., 1985).
Because of this amplification loop, an initial BK activity might
be multiplied by liberated MC-heparin that triggers the contact
system. FXIIa may initiate several protease cascades in plasma,
such as the kallikrein-kinin system, the intrinsic pathway of coag-
ulation, and the complement and fibrinolytic systems (Mu¨ller and
Renne´, 2008). We recently showed that FXIIa-initiated fibrin
formation is essential for arterial thrombus formation (Renne´
et al., 2005a) and ischemia reperfusion injury in experimental
stroke models (Kleinschnitz et al., 2006). Procoagulant FXII266 Immunity 34, 258–268, February 25, 2011 ª2011 Elsevier Inc.activity is initiated by a platelet-secreted inorganic polymer,
polyphosphate. Polyphosphate-activated FXII activates its
substrates FXI and PK, driving the intrinsic pathway of coagula-
tion and the kallikrein-kinin system, respectively (Mu¨ller et al.,
2009). In contrast, heparin specifically triggers FXII-mediated
BK formation. Under these conditions, no proteolytic activation
of FXI is detectable (Figure 2). Similarly, both the nonnatural poly-
saccharide dextran sulfate (Johne et al., 2006) and misfolded
protein aggregates initiate BK formation in a FXII-dependent
manner (Maas et al., 2008). However, these agents do not induce
clotting activity. Because FXI and PK have similar plasma
concentrations and highly homologous structures and are both
bound via HK to cell surfaces (Renne´ et al., 2005b), mechanisms
for cell type-specific activation of the kallikrein-kinin system and/
or the intrinsic clotting pathway may exist that involve distinct
FXII-activation mechanisms, different forms of FXIIa (Schmaier,
2008), effects of the activators on downstream inhibitors (Kishi-
moto et al., 2008), and other yet unknown regulators.
Supporting the concept of selective activation of FXII-driven
pathways, HAE patients suffer from recurrent BK-mediated
swelling but edema attacks are not associated with any
increased prothrombotic risk (Nzeako et al., 2001). Besides the
classical HAE types I and II that are due to a deficiency in or a
dysfunctional C1INH, respectively, a third variant (HAE type III)
with a normal C1INH plasma concentration and function exists.
HAE type III is due to a gain-of-function mutation in FXII that
increases the enzymatic activity of the protease (Cichon et al.,
2006). Similar to our study involving HAE type I and II patients
(Figure 7), edema in HAE type III patients is triggered by allergen
exposure (Bork et al., 2009), supporting a role of heparin for initi-
ating BK-mediated edema in humans. HAE patients (Zuraw,
2008) and our Serping1/ mice (Figure 6) have normal vascular
permeability under nonstimulated conditions. In contrast, previ-
ously generated C1INH-deficient mice have increased basal
vascular permeability (Han et al., 2002). The reason for the
different phenotypes of the two mouse strains might be due to
different technologies used to inactivate the Serping1 gene
coding for C1INH. We used random mutagenesis, which results
in early and complete termination of C1INH protein synthesis,
whereas Han and coworkers used a random insertional muta-
genesis technique (gene trap). The latter technique targets the
Serping1 gene through a retroviral vector that codes for galacto-
sidase and a selection marker. The trapping vector is inserted
into a splice-acceptor site in intron 6 (210 bp 50 of exon 7). This
approach does not abolish Serping1 gene expression but results
in transcription of a C-terminal shortened C1INH variant com-
posed of exons 1–6 (amino acids 1–347 of 504 in the mature
protein) fused to trap-vector coded b-galactosidase (Ullrich
and Schuh, 2009). The biological relevance, i.e., stability, locali-
zation, and interactions, with other proteins of this truncated
C1INH variant is not clear. Although the mutant lacks the active
site (encoded by exon 8), it includes the signal peptide and could
be secreted into the plasma or may modulate intracellular path-
ways that alter basal permeability.
Cumulatively, this study identifies mast cell-heparin as an
in vivo activator of the FXII-driven proinflammatory plasma
contact system. Heparin-initiated BK formation substantially
contributes to swelling, anaphylactic, and inflammatory diseases
associated with aberrant mast cell activity.
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Vascular Permeability Assays
To analyze vascular leakage in real time with intravital laser scanning micros-
copy, we adapted a method originally described for leukocyte infiltration into
vascular lesions (Eriksson et al., 2001). Mice were anesthetized by intraperito-
neal injection of Avertin (2,2,2-tribromoethanol and 2-methyl-2-butanol). Then,
3 ng/g bw FITC-dextran (150 kDa; Sigma-Aldrich) was injected into the retro-
orbital plexus as tracer. A ventral skin window was excised and the skin was
fixed plain. Extravasation of tracer from microvessels (35–60 mm diameter)
was visualized with a Nikon Eclipse E600microscope equipped with a C1 laser
scanning head and a 103 objective. Leakage was assessed for 5 min before
and 30 min after topical application of heparin (20 ml of a 1 mg/ml solution).
Tissue scans were performed at 30 s intervals. Images were analyzed by
EZ-C1 2.10 software (Nikon) and the intensity of extravasated tracer was
quantified with ImageJ 1.34 NIH software. Dorsal skin edema was induced
by intradermal injections of 50 ml heparin (1 mg/ml), C48/80 (50 mg/ml), saline,
histamine (100 mM), BK (100 mM), or Hase-treated heparin (10 mg/ml) (Miles
and Miles, 1952). Some WT mice were pretreated with PCK (8 mg/g bw), Icati-
bant (100 mg/kg bw), or saline 5 min prior to heparin injection. After 30 min, the
mice were sacrificed and the skins were removed and photographed. The
edema site was excised with a circular template of 1.2 cm diameter. For
edema, with diameter >1.2 cm the entire blue area was excised by hand.
Extravasated Evans blue tracer was quantified as described (Donelan et al.,
2006).
Anaphylaxis Models
To induce passive cutaneous anaphylaxis, mice were sensitized by intra-
dermal injection of anti-DNP IgE antibody (1.5 mg/ml) or 50 ml sterile 0.9%
NaCl (control) in the dorsal skin. After 20 hr, we challenged mice by
retro-orbital injection of dinitrophenyl-human serum albumin (7.5 mg/kg bw,
DNP-HSA) together with 10 ml/g bw of 0.25% Evans Blue as described
(Siebenhaar et al., 2008) with minor modifications. Tracer extravasation was
measured as above. For the passive systemic anaphylaxis model, we injected
mice intravenously with anti-DNP IgE (1.25 mg/g bw), challenged them 24 hr
later by intravenous injection of 1 mg DNP-HSA, and recorded arterial blood
pressure by fluid-filled catheter connected to a pressure transducer (APT
300, Harvard Apparatus).
Heparin-Induced BK Generation in Rats
Male rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.,
Nembutal, Ceva). Catheters were placed into the carotid artery and vena
cava and into the jugular artery and vein. The rats were placed in a supine posi-
tion on a heated operating pad. Mean systolic arterial blood pressure was
measured in the left carotid artery with an arterial catheter connected to a
Statham pressure transducer (type P 23 I, Gould) and recorder (LS 64, Linseis).
We applied a bolus of 10 mg/kg bw heparin into the aorta or femoral artery to
trigger hypotension or inflammation, respectively, and continuously monitored
mean arterial blood pressure and vital signs of the animals during challenge.
For some experiments, rats were treated with Icatibant (100 mg/kg bw) prior
to heparin challenge. Plasma was collected from the vena cava for BK deter-
mination and immediately supplemented with protease inhibitors. Frozen
cross-sections of the A. femoralis and V. femoralis 2 mm caudal to the knee
joint were stained with haematoxylin-eosin 30 min after heparin application.
All experiments and animal care were approved by the local Animal Care
and Use committee.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four movies and can be found with this article online at
doi:10.1016/j.immuni.2011.02.008.
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